- Home
- GHLD vs XERS Comparison
GHLD vs XERS Comparison
Compare GHLD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHLD
- XERS
- Stock Information
- Founded
- GHLD 1960
- XERS 2005
- Country
- GHLD United States
- XERS United States
- Employees
- GHLD N/A
- XERS N/A
- Industry
- GHLD Finance: Consumer Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GHLD Finance
- XERS Health Care
- Exchange
- GHLD Nasdaq
- XERS Nasdaq
- Market Cap
- GHLD 1.2B
- XERS 1.3B
- IPO Year
- GHLD 2020
- XERS 2018
- Fundamental
- Price
- GHLD $19.88
- XERS $9.70
- Analyst Decision
- GHLD Hold
- XERS Strong Buy
- Analyst Count
- GHLD 6
- XERS 7
- Target Price
- GHLD $18.10
- XERS $9.43
- AVG Volume (30 Days)
- GHLD 29.0K
- XERS 2.2M
- Earning Date
- GHLD 11-05-2025
- XERS 11-06-2025
- Dividend Yield
- GHLD 3.77%
- XERS N/A
- EPS Growth
- GHLD N/A
- XERS N/A
- EPS
- GHLD 0.42
- XERS N/A
- Revenue
- GHLD $1,125,872,000.00
- XERS $246,025,000.00
- Revenue This Year
- GHLD $1.42
- XERS $43.89
- Revenue Next Year
- GHLD $22.36
- XERS $20.40
- P/E Ratio
- GHLD $47.60
- XERS N/A
- Revenue Growth
- GHLD 23.19
- XERS 35.62
- 52 Week Low
- GHLD $11.21
- XERS $2.82
- 52 Week High
- GHLD $23.57
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- GHLD 48.38
- XERS 70.83
- Support Level
- GHLD $19.83
- XERS $9.11
- Resistance Level
- GHLD $19.93
- XERS $10.03
- Average True Range (ATR)
- GHLD 0.07
- XERS 0.42
- MACD
- GHLD -0.01
- XERS 0.04
- Stochastic Oscillator
- GHLD 47.83
- XERS 84.41
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).